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Abstract
Introduction: Ethiopia has recently adopted lifelong antiretroviral therapy (ART) for all HIV-positive pregnant and breastfeeding
women (Option B strategy), regardless of CD4 count or clinical stage. However, the exact timing and predictors of loss to
follow-up (LFU) are unknown. Thus, we examined the levels and determinants of LFU under Option B among pregnant and
breastfeeding women initiated on lifelong ART for prevention of mother-to-child transmission (PMTCT) in Ethiopia.
Methods: We conducted a retrospective cohort study among 346 pregnant and breastfeeding women who started ART at
14 public health facilities in northeast Ethiopia from March 2013 to April 2015. We defined LFU as 90 days since the last clinic
visit among those not known to have died or transferred out. We used Kaplan-Meier and Cox proportional hazards regression to
estimate cumulative LFU and identify the predictors of LFU, respectively.
Results: Of the 346 women included, 88.4% were pregnant and the median follow-up was 13.7 months. Overall, 57 (16.5%)
women were LFU. The cumulative proportions of LFU at 6, 12 and 24 months were 11.9, 15.7 and 22.6%, respectively. The risk of
LFU was higher in younger women (adjusted hazard ratio (aHR) 18 to 24 years/30 to 40 years: 2.3; 95% confidence interval (CI):
1.2 to 4.5), in those attending hospitals compared to those attending health centres (aHR: 1.8; 95% CI: 1.1 to 3.2), in patients
starting ART on the same day of diagnosis (aHR: 1.85; 95% CI: 1.1 to 3.2) and missing CD4 cell counts at ART initiation (aHR: 2.3;
95% CI: 1.2 to 4.4).
Conclusions: The level of LFU we found in this study is comparable with previous findings from other resource-limited settings.
However, high early LFU shortly after ART initiation is still a major problem. LFU was high among younger women, those
initiating ART on the day of HIV diagnosis, those missing baseline CD4 count and those attending hospitals. Thus, targeted HIV
care and treatment programmes for these patients should be part of future interventions to improve retention in care under the
Option B PMTCT programme.
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Introduction
In 2013, an estimated 3.2 million children under the age of
15 were living with HIV globally, 91% of whom were in
sub-Saharan Africa [1]. Mother-to-child transmission (MTCT)
of HIV remains the primary mode of infection in children [2].
Timely access to quality life-saving antiretroviral (ARV) drugs
during and after pregnancy is a proven intervention to
preserve maternal health and virtually eliminate the risk of
MTCT of HIV [2,3].
In 2010, the World Health Organization (WHO) published
prevention of mother-to-child transmission (PMTCT) guide-
lines. The guidelines specify that a CD4 count is crucial to
decisions on the eligibility of HIV-positive pregnant women
for lifelong antiretroviral therapy (ART) [4]. In 2013, the
WHO issued a new guideline recommending lifelong ART for
all HIV-positive pregnant and breastfeeding women, regard-
less of their CD4 count or WHO clinical stage (Option B ) [5].
The rationale of this policy was to achieve the elimination of
new paediatric HIV infections by 2015 and ensure that all
ART-eligible pregnant women receive triple ARVs for their own
health [5,6]. This approach is believed to contribute to the
target of ending the AIDS epidemic by 2030 [7].
Option Bmay be amore effective PMTCTstrategy, as it can
help overcome some barriers (like poor access to CD4 testing)
associated with achieving high coverage of treatment [8].
This approach ensures that most HIV-positive women are
placed on treatment immediately following diagnosis, which
leads to further reduction of MTCT [8]. Moreover, the sim-
plification of drug regimen options could make adherence
easier for both mother and healthcare provider, which is likely
to facilitate higher retention rates [9,10]. Additionally, Option
B provides an excellent opportunity to begin roll-out
of ‘‘treatment as prevention,’’ which can have a significant
impact in reducing new HIV infections due to sexual trans-
mission among serodiscordant partners [9].
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The implementation of Option B has already begun to
show impressive results in resource-constrained settings
dramatically increasing the numbers of pregnant and breast-
feeding women enrolled on ART [9]. The gains sought by
expanding ART access through Option B depend on the
proportion of women who adhere to treatment and are
retained in care. However, these gains in access are being
challenged by high loss to follow-up (LFU) and non-adherence
to treatment that significantly undermines success of Option
B [11,12]. As an illustration, in Malawi, 17% of women in
Option B are lost to follow-up six months after ART initiation
[13]. Poor retention in care or adherence to treatment could
be a threat to both HIV-positive women and their infants.
Retention in HIV care is one of the crucial indicators of
the success of ART programmes [14,15]. Poor retention due
to LFU is associated with virological failure, development of
potent drug-resistant virus as well as maternal HIV disease
progression and increased risk of MTCT [16,17].
One of the challenges when analyzing the potential
effectiveness of PMTCT interventions is LFU of mothers
[18,19]. Several reasons may explain why women starting ART
do not attend their follow-up appointments. Some qualitative
studies have identified factors contributing to LFU under
the Option B programme including lack of motivation to
adhere to lifelong medication after a healthy delivery [18,19],
denial or lack of disclosure of HIV status [20] and not feeling
ready to embark on lifelong medication [19]. In addition, high
LFU was reported among younger women and women who
initiated ART during pregnancy [21].
In 2013, Ethiopia launched Option B as a national policy
to prevent MTCT. This ART policy was implemented in
a phased approach, prioritizing health centres that provide
both PMTCTand ART services [22]. To date, with the exception
of one adherence study [23], there are no published studies
concentrating on LFU under this new modality in Ethiopia.
Further examination of LFU and its risk factors among women
starting ART under the Option B strategy is warranted.
The objectives of this analysis were to determine the
levels, timings and determinants of LFU under Option B
among pregnant and breastfeeding women initiating lifelong
ART at 14 public health facilities in northeast Ethiopia. The
findings of this study will assist in developing evidence-based
interventions to promote retention in care, such that the
health benefits of Option B can be fully realized.
Methods
Ethiopian national PMTCT programme
HIV-positive pregnant and breastfeeding women start on
lifelong ART (fixed-dose combination of tenofovir/lamivudine/
efavirenz) regardless of their immunological status in accor-
dance with the Option B strategy stipulated in Ethiopia’s
comprehensive guidelines for PMTCT/maternal, neonatal
and child health (MNCH) [22]. All pregnant women, except
those with advanced HIV disease (WHO Stage 3 and 4) and
opportunistic infections (OIs), start on ART during antenatal
care. Pregnant women with advanced disease are referred
to an ART clinic for diagnosis and treatment of the OI and
initiation of ART. They are then transferred back to PMTCT for
their ongoing care and treatment. The guideline recommends
that tracing of women lost to care be initiated within seven
days of a missed appointment.
Study setting
The study was implemented at public health institutions
located in three zones (including South Wollo, North Wollo
and the Oromia special zone) of the Amhara region in
northeast Ethiopia. We selected 14 facilities based on the
numbers of women on ART and accessibility to study staff for
data collection. The selected facilities included the following:
one referral hospital, three general hospitals and 10 urban
health centres. All of the health facilities provide integrated
MNCH/PMTCT services to HIV-positive women free of charge.
All the facilities used a similar model of PMTCT delivery,
in which HIV-positive women were initiated on ART and
followed up at the antenatal clinic. Clinic appointments
were typically scheduled one to three months apart, based
on patient’s clinical status.
Study design and population
We conducted a retrospective cohort study of women who
started ART under the new Option B treatment guidelines
between 8 March 2013 and 13 April 2015. Only patients who
enrolled at least three months prior to the end of data
collection were eligible to be included in the sample, so that all
patients had the opportunity to meet the definition for LFU.
Women whose reason for starting ART was unknown were
excluded. At each site, patients matching inclusion criteria
were identified using MNCH registers covering the study time
periods. Medical record numbers were retrieved from this
registry and used to find each individual’s patient card.
Study variables and data collection
In this study, the explanatory variables were baseline demo-
graphic characteristics and clinical variables including age
at ART initiation, marital status, education, religion, place
of residence (urban/rural), baseline weight, pregnancy status
(pregnant/breastfeeding), time between diagnosis and ART
initiation (started ART same day of HIV diagnosis/started
ART later), CD4 cell count at ART initiation,WHO clinical stage
(Stage 1/2 vs. 3) and year of ART initiation. Health facility type
(hospital vs. health centre) was also included. Baseline CD4
cell counts were taken as the CD4 cell count nearest to ART
initiation, using a window of three months before and one
month after the date of ART initiation. For most patients, data
on CD4 cell count were missing. We therefore created
dummy variables that indicated whether or not CD4 cells had
been assessed within a window period of three months prior
to and one month after ART initiation.
The data sources were the Federal Ministry of Health
patient card, ART intake forms, HIV care follow-up and the
PMTCT register. Trained nurses working in the ART clinic/
PMTCT extracted the data using a structured tool prepared
for the study. The data abstraction tool for chart review was
prepared based on the information contained within the
patient registration and follow-up card.
Study outcomes and definitions
The primary outcome of this study was LFU. LFU was defined
as 90 days after the last documented visit, as per the recently
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developed simplified tools to measure retention in care in
ART programmes [24]. Time to LFU was a secondary end
point of the study. We estimated follow-up time on ART
as the time between ART initiation and either documented
transfer out, LFU (as defined above) or completion of obser-
vation period (13 April 2015), whichever occurred first. For
those who never attended a follow-up visit we defined time
to LFU as the time from ART initiation to 15 days after the
ART initiation. Patients who had documentation of transfer
out were censored at the date of transfer or last visit date,
whichever was later.
Data analysis
EpiData version 3.1 was used for data entry and STATA version
11 (StataCorp, College Station, TX, USA) for statistical analyses.
We used medians and interquartile ranges (IQRs) for contin-
uous variables and proportions for categorical variables
to describe baseline characteristics. Proportions LFU at 6, 12
and 24 months after ART initiation were estimated using
Kaplan-Meir methods. Cox proportional hazards regression
models with robust sandwich estimates to account for within-
facility correlations were used to examine the relationships
of individual and facility-related independent variables with
the risk of LFU. We included all the variables associated
with LFU in the univariate analysis (at the pB0.20 level) in
the multivariable Cox regression model. Associations were
estimated using hazard ratios with 95% confidence intervals
(CI). Finally, associations were examined at a significance level
of pB0.05 (two-sided test).The proportional hazards assump-
tion was checked by graphical methods and using Schoenfeld
residuals tests and the results of these analyses suggested
that the proportional hazards assumption appeared to be
reasonable.We used both the Akaike and Bayesian information
criteria (AIC/BIC) to assess model parsimony.
Ethical consideration
Ethical approval for this study was granted by the Research
Ethics Committee of Wollo University and exemption was
given by the respective local authority where the study was
implemented. The study utilized data that are routinely
collected for service delivery and anonymized for analysis;
thus we did not seek patient consent.
Results
Between 8 March 2013 and 13 April 2015, a total of 418 HIV-
positive women started ART under Option B at one of
the 14 public health facilities included in the study. Of these,
42 were excluded from the study because their charts could
not be found. Of the 376 remaining women, 30 were excluded
because their reason for starting ART was unknown (n17)
or due to data inconsistencies (n13), resulting in a final
total of 346 women for further analysis (Figure 1). About two-
thirds of the patients (67.3%) were enrolled at public health
centres; the remaining 15.9 and 16.8% started ART at referral
and general hospitals, respectively.
Patient characteristics at ART initiation
The demographic characteristics of the study population at
ART initiation are shown in Table 1. The median (IQR) age
at ART initiation was 26 (23 to 30) years. A majority of
women (80.3%) were married, and 88.7% were urban
residents. Nearly half (51.2%) were Orthodox Christian and
45.7% were Muslims. Most patients received either no
formal education (30.3%) or education only up to the primary
level (36.1%); 4.3% had incomplete information on level of
education. The median (IQR) weight at ART initiation was
55 (50 to 61) kg and more than half (55.5%) of patients had
body weight less than 55 kg. Overall, 89.7% (289) of women
were pregnant and the median (IQR) gestational age at ART
initiation was 20 weeks (IQR: 15 to 26).
Overall, 234 (67.9%) women had at least one recorded CD4
cell count. Of these, 134 (57.3%) had a CD4 cell count within
a window of three months prior to and one month after ART
initiation (three were missing a date for CD4 cell count). The
median CD4 was 460 (IQR: 277 to 638) cells/mL. The majority
(70.5%) were classified as WHO Clinical Stage 1, followed by
those classified as Stage 2 (23.1%) and Stage 3 (6.6%). None
of the patients were classified as WHO Clinical Stage 4. Of
the patients with a known HIV-testing date, 147 (42.5%)
began ART on the day they were diagnosed (three were
missing HIV-testing date). The median (IQR) time from
diagnosis to ART initiation was 3 (0 to 180) days.
Loss to follow-up
Overall, 57 (16.5%) of women were LFU during the observa-
tion period. Of the 57 women LFU, 16 (28.0%) had no follow-
up visit after the initiation of ART. The cumulative proportion
of patients LFU at 6, 12 and 24 months after ART initiation
was 11.9% (95% CI: 8.9, 16.0%), 15.7% (95% CI: 12.0, 20.4%)
and 22.5% (95% CI: 17.3, 29.2%), respectively (Figure 2).
The overall incidence of LFU among all women, including
those who attended no follow-up visit, was 14.8 per 1000
person-years (PY) of observation time (95% CI: 11.4 to 19.2)
with a median follow-up of 10.8 months (IQR: 4.5 to 16.7).
The LFU rate was high during the first six months of ART
initiation (29.1/1000 PY) but fell with increasing time in
follow-up, with LFU rates of 14.0/1000 PY and 7.5/1000 PY at
12 and 24 months, respectively.
Factors associated with LFU
In bivariate analysis, LFU differed significantly from non-LFU
in terms of age at ART initiation, baseline weight, facility
level, ART initiation from the day of diagnosis and knowledge
of baseline CD4 cell count (Table 2).
In adjusted analyses, the independent risk factors for LFU
were as follows: younger age at ART initiation, missing CD4
cell count at ART initiation, ART initiation on the same day of
diagnosis and starting ART at hospital. In unadjusted analyses,
weight at ART initiation was associated with LFU, but this was
not significant after controlling for other variables.
Discussion
This is the first study carried out in Ethiopia to report on
the levels and determinants of LFU under universal lifelong
ART for pregnant and breastfeeding women (Option B ).
Approximately 16% of women in the PMTCT Option B
programme were LFU. Younger age, missing CD4 count at ART
initiation, starting ART on the same day of diagnosis and
starting ART at hospital were found to be the risk factors
for LFU.
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The LFU observed in this study is lower compared to
previous study findings from Malawi, in which 17% [13,25]
and 22% 11 of all women were lost 6 and 12 months
after ART initiation, respectively. However, the fact that the
definition of LFU varied in each programme or study
complicates the comparison between different settings [26].
About 12% of LFU occurred within the first six months of
ART initiation. Early patient losses under Option B have
also been reported from other African settings [13]. Previous
studies from Ethiopia [2729] and other African countries
[30,31] have also documented higher risk of attrition in
the first six months of ART among adults in the general
population. These findings suggest that the initial time period
after a patient initiates ART is the most critical to focus
efforts aimed at improving retention [31].
In this study, 28.1% of women who were LFU received ARVs
only once and never returned for their appointment, suggest-
ing that a proportion of these women never started ART or
stopped after the first dose in the health facility. Our finding
is lower than a report from Malawi, where 47% of women
collected ART at initiation and never returned for their
appointment [21]. The difference could be due to differences
in the model of PMTCT service delivery and also differences
between the study settings [32]. Studies have attributed high
dropout rates for Option B to resistance to starting lifelong
ART. Women may have been less well prepared for ART and
thus less likely to attend follow-up visits [19,33]. This idea is
supported by our finding of the association between the time
between HIV diagnosis and ART initiation and LFU.
Women who started ART on the day they were diagnosed
had a higher risk of LFU than women who started ART later.
This finding has been documented elsewhere [13]. Previous
studies have suggested that women who start ART immedi-
ately after diagnosis do not have the chance to disclose their
HIV status, and prior disclosure may improve ART adherence
[18,34]. Lack of disclosure related to stigma and lack of male
partner involvement has also been reported to deter post-
partum women in HIV care under Option B [18]. Moreover,
women’s lack of readiness at ART initiation could result
in interrupted treatment [35]. Empirical evidence regarding
the advantages of systematically delayed ART is limited [36].
Giving sufficient time and information might help clients
adjust to the idea of lifetime treatment, but this possibility
needs to be better documented.
The other significant factor associated with LFU in our study
was women’s age at ART initiation. Women who were 18 to
24 years at ART initiation were more likely to be LFU than
older women. This finding has been observed by others [21].
Our findings are consistent with the findings reported in
the general HIV-positive population accessing ART for perso-
nal health [37,38]. Multiple factors may contribute to higher
LFU among younger women. One possible explanation for this
finding could be lack of belief in the benefits of attending
clinic and initiating ART among these women [39]. In contrast,
14 Transferred to other 
facility
418 women started ART at 14 health facilities between March 2013
and April 2015
42 Patients with missing medical records
17 patients with unknown reason for starting 
ART
13 Patients with data in consistencies
57 LTF
346 patients included in the analysis
275 Alive and on treatment at 
facility
Figure 1. CONSORT diagram with total number of eligible patients and number of patients included in the analysis.
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Characteristics n % n % n % p
Age at ART initiation
18 to 24 121 35.0 33 57.9 88 30.4 0.042
25 to 29 138 39.9 12 21.1 126 43.6 0.190
30 to 40 87 25.1 12 21.1 75 26.0
Place of residence
Urban 307 88.7 49 86.0 258 89.3
Rural 39 11.3 8 14.0 31 10.7 0.352
Marital status
Married 290 83.8 45 78.9 245 84.8
Single 26 7.5 5 8.8 21 7.3 0.454
Divorced/widower 30 8.7 7 12.3 23 7.9 0.374
Religion
Orthodox 177 52.4 34 59.6 143 50.9
Muslim 158 49.7 23 40.4 135 48.0
Protestant 3 0.9 0 0.0 3 1.1
Missing 8
Educational status
No education 105 31.7 17 31.5 88 31.8
Primary 125 37.8 23 42.6 102 36.8 0.563
Secondary 84 25.4 10 26.7 74 26.7 0.414
Tertiary 17 5.1 4 7.4 13 4.7 0.614
Missing 15
Pregnancy status at enrolment
Pregnant 306 88.4 53 93.0 253 87.5
Breastfeeding 40 11.6 4 7.0 36 12.5 0.255
Weight at ART initiation (kg)
555 134 38.7 27 47.4 165 57.7 0.168
55 212 61.3 30 52.6 121 42.3
Missing
WHO clinical stage at ART initiation
Stage 1/2 54 94.7 270 93.4 0.894
Stage 3 3 5.3 19 6.6
Facility level
Health centre 232 67.1 31 54.4 201 69.5
Hospital 114 32.9 26 45.6 88 30.5 0.036
Started ART on the day of diagnosis
No 196 57.1 23 40.4 173 60.5 B0.001
Yes 147 42.9 34 59.6 113 39.5
Missing 3
Year of ART initiation
2015 56 16.2 5 8.8 51 17.6
2014 185 53.5 35 61.4 150 51.9 0.865
2013 105 30.3 17 29.8 88 30.4 0.331
CD4 cell count done near (3 months before and
1 month after) ART initiation
Yes 324 93.6 13 22.8 121 41.9
No 22 6.4 44 77.2 168 58.1 0.004
ART, antiretroviral therapy; LFU, lost to follow-up.
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older women may have more settled lifestyles, which allow
them to better manage ARVs for PMTCT [21]. Young women
might be concerned about starting treatment for life at such
a young age [20]. These findings highlight the need to focus
efforts toward retaining this group in HIV care.
In our analysis, we found that LFU was likely among
women with missing data on CD4 cell count at ART initiation.
There are speculations that patient’s knowledge of CD4 count
could influence initiation and adherence to ART [40]. One
of the possible explanations could be that testing CD4 cell
count at the first visit raises women’s HIV-related literacy
and awareness and might engage women in care. The use of
point-of-care CD4 count technology has been recommended
as one strategy to improve patient retention in pre-ART
care [41,42]. In this study, only 38.7% had a CD4 cell count
within a window of three months prior to and one month
after ART initiation. Although CD4 count is no longer a
prerequisite for initiating intervention for HIV-positive preg-
nant women, the national PMTCT guideline recommends that
CD4 count be done as soon as possible as a baseline and for
monitoring purposes [22]. The possibility that providing
women with their CD4 count at the time of ART initiation
might change the attitudes of women toward lifelong
care, and thus result in different levels of retention in care,
has been recommended as a priority for further operational
research [40].
Additionally, LFU was significantly associated with health
facility type. A higher hazard of LFU was observed among
women attending hospitals compared to those attending
primary facilities (health centres). Similar findings were
reported by Tenthani et al. [13]. from a cohort in Malawi
in which LFU was also associated with larger health facilities.
Our finding confirms earlier observations of increased risk
of attrition among patients attending higher level healthcare
facilities [13,43]. It may be related to less favourable health-
system factors in larger ART programmes, such as patient
burden per staff member and longer waiting times [44].
Misclassification of patients as LFU has also been reported
to be more common in larger facilities, as these facilities are
located in more urban regions with a mobile population [13].
Being pregnant at ART initiation has been shown to be an
independent indicator of LFU among HIV-positive women in
sub-Saharan Africa [21]. However, we did not find a similar
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Figure 2. Kaplan-Meier estimates of loss to follow-up among
women starting antiretroviral therapy under Option B from
March 2013 to April 2015, Ethiopia.
Table 2. Baseline demographic and clinical characteristics associated with LFU among women who started ART under Option
B from March 2013 to April 2015, Ethiopia
Characteristics Unadjusted HR (95% CI) Adjusted HR (95% CI) p
Age at ART initiation
18 to 24 1.98 (1.1 to 3.8) 2.3 (1.2 to 4.5) 0.017
25 to 29 0.59 (0.26 to 1.30) 0.67 (0.3 to 1.5) 0.325
30 to 40 1.00 1.00
Weight at enrolment (kg)
555 1.00 1.00
55 1.42 (0.86 to 2.41) 1.3 (0.8 to 2.3) 0.348
Facility level
Health centre 1.00 1.00
Hospital 1.75 (1.04 to 2.96) 1.8 (1.1 to 3.2) 0.039
Started ART on the day of diagnosis
No 1.00 1.00
Yes 2.56 (1.51 to 4.32) 1.9 (1.1 to 3.2) 0.032
CD4 cell count done near (3 months before
and 1 month after) ART initiation
Yes 1.00 1.00
No 2.47 (1.34 to 4.56) 2.3 (1.2 to 4.4) 0.010
Note:Multivariable analysis adjusted for all variables shown in table. Hazard ratios estimated using robust sandwich estimators for variance to account
for within-clinic correlation. HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy. Values in bold are statistically significant at P50.05.
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Though we used patient data collected as part of routine
service delivery, the comprehensiveness of patient medical
records allowed us to evaluate certain patient-level factors
that were previously associated with retention. Availability
of HIV-testing date allowed us to describe time elapsed
between HIV testing, ART initiation and patient outcomes.
The study has some potential limitations. These limita-
tions were mainly related to data abstraction of routinely
collected programme data; hence, we could not measure
certain patient-level factors and societal factors. The data
for CD4 cell counts for most women were not complete,
either because they were not determined or if determined not
registered. Another limitation of the study was the use of
the pregnant women’s weight at ART initiation, which
changes continuously and substantially. In addition, patients
whose medical record was not found were not included in
the analysis, which might have affected the true level of
LFU. Finally, we could not independently verify outcomes for
those who were classified as LFU. It is possible that some
patients may have been classified as LFU due to undocumen-
ted transfers or undocumented death.
Conclusions
In conclusion, the level of LFU we found in this study is similar
to previous findings from other resource-limited settings. High
early LFU shortly after ART initiation is a major problem. LFU
was high among younger women, those initiating ART on the
day of HIV diagnosis, those missing baseline CD4 count and
those attending larger hospitals. Nonetheless, we recommend
additional large-scale research to ascertain to what extent
time between HIV diagnosis and ART initiation and knowledge
of baseline CD4 count are associated with women’s retention
in care. Targeted HIV care and treatment programmes for
these patient subgroups should be part of future interventions
to improve retention in care under Option B.
Authors’ affiliations
1Department of Public Health, College of Medicine and Health Sciences, Wollo
University, Dessie, Ethiopia; 2Department of Preventive Medicine, School of
Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa,
Ethiopia
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
IM conceived and designed the study. IM and MA performed data abstraction
and analyzed the data. IM wrote the draft manuscript. All the authors critically
appraised the manuscript and approved the final version of the manuscript for
publication.
Acknowledgements
We gratefully acknowledge Wollo University for financial support to conduct
this study. We would like to extend our gratitude to the North Wollo, South
Wollo and Oromia administrative zone health departments for their valuable
support during implementation of the study. Finally, we would like to thank all
healthcare providers who helped us get all necessary data used in the analyses.
References
1. UNAIDS. Progress report on the global plan: towards the elimination of new
HIV infections among children by 2015 and keeping their mothers alive.
Geneva, Switzerland: UNAIDS; 2014.
2. World Health Organization. PMTCT strategic vision 20102015: preventing
mother-to-child transmission of HIV to reach the UNGASS and Millennium
Development Goals. Geneva: World Health Organization; 2010.
3. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey
PA. Low rates of mother-to-child transmission of HIV following effective
pregnancy interventions in the United Kingdom and Ireland, 20002006. AIDS.
2008;22:97381.
4. World Health Organization. Antiretroviral drugs for treating pregnant
women and preventing HIV infections in infants: Recommendations for a
public health approach. Geneva, Switzerland: World Health Organization; 2010.
5. World Health Organization. Consolidated guidelines on the use of anti-
retroviral drugs for treating and preventing HIV infection. Geneva, Switzerland:
World Health Organization; 2013.
6. UNAIDS. Global plan towards the elimination of new HIV infections among
children by 2015 and keeping their mothers alive. Geneva, Switzerland:
UNAIDS; 2011.
7. UNAIDS. Press statement. Global leaders commit to ending the AIDS
epidemic in cities by 2030. Geneva, Switzerland: UNAIDS; 2014.
8. Schouten EJ, Jahn A, Midiani D, Makombe SD, Mnthambala A, Chirwa Z,
et al. Prevention of mother-to-child transmission of HIV and the health-related
Millennium Development Goals: time for a public health approach. Lancet.
2011;378:2824.
9. UNICEF. Options B and B: key considerations for countries to implement
an equity-focused approach: eliminating new HIV infections among children
and keeping mothers living with HIV alive and well July 2012 [Internet]. [cited
2015 Sept 10]. Available from: http://www.unicef.org/aids/files/hiv_Key_
considerations_options_B.pdf
10. Hirnschall G, Schwartlander B. Treatment 2.0: catalysing the next phase of
scale-up. Lancet. 2011;378:20911.
11. CDC. Impact of an innovative approach to prevent mother-to-child
transmission of HIV-Malawi, July 2011-September 2012. Morb Mortal Wkly
Rep. 2013;62(08):14851.
12. Keehn E, Karfakis J. Current practices to increase uptake, retention and
adherence for Option B in Malawi. Lilongwe: mothers2mothers Malawi;
2014.
13. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F,
et al. Retention in care under universal antiretroviral therapy for HIV-infected
pregnant and breastfeeding women (‘‘Option B ’’) in Malawi. AIDS. 2014;
28:58998.
14. Clouse K, Pettifor AE, Maskew M, Bassett J, Van Rie A, Behets F, et al.
Patient retention from HIV diagnosis through one year on antiretroviral
therapy at a primary health care clinic in Johannesburg, South Africa. Acquir
Immune Defic Syndr. 2013;62(2):3946.
15. Crum NF, Riffenburgh RH,Wegner S, Agan BK, Tasker SA, Spooner KM, et al.
Comparisons of causes of death and mortality rates among HIV-infected
persons: analysis of the pre, early, and late HAART (highly active antiretroviral
therapy) eras. J Acquir Immune Defic Syndr. 2006;41(2):194200.
16. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al.
Adherence to protease inhibitor therapy and outcomes in patients with HIV
infection. Ann Intern Med. 2000;133(1):2130.
17. Nachega JB, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF,
et al. Adherence to antiretroviral therapy during and after pregnancy in low-
income, middle-income, and high-income countries: a systematic review and
meta-analysis. AIDS. 2012;26(16):203952.
18. Clouse K, Schwartz S, Van Rie A, Bassett J, Yende N, Pettifor A. What
they wanted was to give birth; nothing else’’: barriers to retention in option
B HIV care among postpartum women in South Africa. Acquir Immune Defic
Syndr. 2014;67:e128.
19. Ngarina M, Tarimo EAM, Naburi H, Kilewo C, Mwanyika-Sando M,
Chalamilla G, et al. Women’s preferences regarding infant or maternal
antiretroviral prophylaxis for prevention of mother-to-child transmission of
HIV during breastfeeding and their views on Option B in Dar es Salaam,
Tanzania. PLoS One. 2014;9(1):e85310. doi: http://dx.doi.org/10.1371/journal.
pone.0085310
20. Global Network of People Living with HIV and International Community
of Women Living with HIV/AIDS. Understanding the perspectives and/or
experiences of women living with HIV regarding Option B in Uganda and
Malawi. Amsterdam: GNP; 2013.
21. Tweya H, Gugsa S, Hosseinipour H, Speight C, Ng’ambi W, Bokosi M, et al.
Understanding factors, outcomes and reasons for loss to follow-up among
women in Option B PMTCT programme in Lilongwe, Malawi. Trop Med Int
Health. 2014;19(11):13606.
Mitiku I et al. Journal of the International AIDS Society 2016, 19:20662
http://www.jiasociety.org/index.php/jias/article/view/20662 | http://dx.doi.org/10.7448/IAS.19.1.20662
7
22. Federal Ministry of Health. National comprehensive PMTCT/MNCH/RH
training package guideline reference manual. Addis Ababa: Federal Ministry of
Health; 2013.
23. Ebuy H, Yebyo H, Alemayehu M. Level of adherence and predictors of
adherence to the Option B PMTCT programme in Tigray, northern Ethiopia.
Int J Infect Dis. 2015;33:e1239.
24. Assefa Y, Worku A, Wouters E, Koole O, Haile Mariam D, Van Damme W.
Simplified tools for measuring retention in care in antiretroviral treatment
program in Ethiopia: cohort and current retention in care. PLoS One. 2012;
7(6):e38555. doi: http://dx.doi.org/10.1371/journal.pone.0038555
25. Government of Malawi Ministry of Health. Integrated HIV Program Report.
2012.
26. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy
programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007;4(10):
e298. doi: http://dx.doi.org/10.1371/journal.pmed.0040298
27. Assefa Y, Kiflie A, Tesfaye D, Hailemariam D, Kloos H, Edwin W, et al.
Outcomes of antiretroviral treatment program in Ethiopia: retention of
patients in care is a major challenge and varies across health facilities. BMC
Health Serv Res. 2011;11:81. doi: http://dx.doi.org/10.1186/472-6963-11-81
28. Assefa Y, Van Damme W, Haile Mariam D, Kloos H. Toward universal
access to HIV counseling and testing and antiretroviral treatment in Ethiopia:
looking beyond HIV testing and ART initiation. AIDS Patient Care STDS. 2010;
24(8):5215. doi: http://dx.doi.org/10.1089/apc.2009.0286
29. Mekuria LA, Prins JM, Yalew AW, Sprangers MAG, Nieuwkerk PT. Retention
in HIV care and predictors of attrition from care among HIV-infected adults
receiving combination anti retroviral therapy in Addis Ababa. PLoS One.
2015;10(6):e0130649. doi: http://dx.doi.org/10.1371/journal.pone
30. Rasschaert F, Koole O, Zachariah R, Lynen L, Manzi M, Van Damme W.
Short and long term retention in antiretroviral care in health facilities in rural
Malawi and Zimbabwe. BMC Health Serv Res. 2012;12:444.
31. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A, Nash D, et al. Early
loss of HIV-infected patients on potent antiretroviral therapy programs in
lower-income countries. Bull World Health Organ. 2008;86(7):55967.
32. van Lettow M, Bedell R, Mayuni I, Mateyu G, Landes M, Chan AK, et al.
Towards elimination of mother-to-child transmission of HIV: performance of
different models of care for initiating lifelong antiretroviral therapy for
pregnant women in Malawi (Option B ). J Int AIDS Soc. 2014;17:18994.
doi: http://dx.doi.org/10.7448/IAS.17.1.18994
33. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS
Rep. 2005;2(4):1716.
34. Gebrekristos HT, Mlisana KP, Karim Q. Patients’ readiness to start highly
active antiretroviral treatment for HIV. BMJ. 2005;331:7725.
35. Enriquez M, Lackey NR, O’Connor MC, Mckinsey DS. Successful adherence
after multiple HIV treatment failures. J Adv Nurs. 2004;45:43846.
36. Myer L, Zulliger R, Bekker LG, Abrams E. Systemic delays in the initiation
of antiretroviral therapy during pregnancy do not improve outcomes of HIV-
positive mothers: a cohort study. BMC Pregnancy Childbirth. 2012;12:94.
37. Ochieng-Ooko V, Ochieng D, Sidle JE, Holdsworth M, Wools-Kaloustian
K, Siika AM, et al. Influence of gender on loss to follow-up in a large
HIV treatment programme in western Kenya. Bull World Health Organ.
2010;88(9):6818. doi: http://dx.doi.org/10.2471/BLT.09.064329
38. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, Viola V, Mutabazi
V, Alwar T, et al. High attrition before and after ART initiation among youth
(1524 years of age) enrolled in HIV care. AIDS. 2014;28(4):55968.
39. World Health Organization. Retention in HIV programmes: defining the
challenges and identifying solutions. Geneva: World Health Organization; 2012.
40. Mangwiro AZ, Makomva K, Bhattacharya A, Bhattacharya G, Gotora T,
Mushavi A, et al. Does provision of point-of-care CD4 technology and early
knowledge of CD4 levels affect early initiation and retention on antiretroviral
treatment in HIV-positive pregnant women in the context of Option B for
PMTCT? J Acquir Immune Defic Syndr. 2014;67:S13944.
41. Faal M, Naidoo N, Glencross DK, Venter WD, Osih R. Providing immediate
CD4 count results at HIV testing improves ART initiation. J Acquir Immune Defic
Syndr. 2011;58:e549.
42. Jani I, Sitoe N, Alfai E, Chongo P, Lehe J, Rocha B, et al. Point-of-care CD4
improves patient rentention and time-to-initiation of ART in Mozambique.
XVIII International AIDS Conference; Vienna, Austria; Jul 1823, 2010. Abstract
FRLBE101.
43. Fatti G, Grimwood A, Bock P. Better antiretroviral therapy outcomes at
primary healthcare facilities: an evaluation of three tiers of ART services in four
South African Provinces. PLoS One. 2010;5(9):e12888. doi: http://dx.doi.org/
10.1371/journal.pone.0012888
44. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, et al.
Temporal changes in programme outcomes among adult patients initiating
antiretroviral therapy across South Africa, 20022007. AIDS. 2010;24(14):
226370.
Mitiku I et al. Journal of the International AIDS Society 2016, 19:20662
http://www.jiasociety.org/index.php/jias/article/view/20662 | http://dx.doi.org/10.7448/IAS.19.1.20662
8
